Home/Pipeline/AGA2118

AGA2118

Osteoporosis

Phase 2Active

Key Facts

Indication

Osteoporosis

Phase

Phase 2

Status

Active

Company

Angitia Biopharmaceuticals

About Angitia Biopharmaceuticals

Angitia Biopharmaceuticals is a private, clinical-stage biotech with a focused pipeline of three biologic candidates targeting high-need musculoskeletal conditions, including osteoporosis and osteogenesis imperfecta. The company is led by industry veteran Dr. Hua Zhu (David) Ke, who previously contributed to the development of blockbuster bone drugs like Prolia and Evenity. With a strong financial position bolstered by a recent $130M Series D round in 2026, Angitia is advancing multiple Phase 2 trials globally while building on a foundation of proven scientific acumen in bone biology.

View full company profile

Therapeutic Areas

Musculoskeletal Diseases Osteoporosis Osteogenesis Imperfecta Spinal Disorders

Other Osteoporosis Drugs

Drug	Company	Phase	Status
Biosimilar to Prolia® (denosumab)	Teva	Approved/Under Review	Launched in EU, under review in US
Teriparatide	Epygen Biotech	Not Disclosed	Active
Teriparatide (PTH 1-34) Process	Numaferm	Commercial	Active
Recombinant Teriparatide	Paras Biopharmaceuticals Finland	Pre-clinical	Active
Stoboclo®/Osenvelt®	Celltrion	Marketed	Approved
SHR-1222	Jiangsu Hengrui Medicine	Phase III	Active
Biosimilar Denosumab	Richter Gedeon	Phase III	Active
Teriparatide Injection	Amphastar Pharmaceuticals	Marketed	Generic (Launched)
TST002 (Blosozumab)	Transcenta Therapeutics	Phase 1	Active